# Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo

> **NCT07557693** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 5 (estimated)

## Conditions studied

- Vitiligo Vulgaris

## Interventions

- **DRUG:** OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL

## Key facts

- **NCT ID:** NCT07557693
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557693, "Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07557693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*